Details:
ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spinal fusion procedures.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spinal fusion procedures.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
ALLOB (allogeneic bone cell therapy) is an allogeneic osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells. It represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells into bone-forming cells.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pregene
Deal Size: $53.6 million Upfront Cash: $9.7 million
Deal Type: Termination October 07, 2022
Details:
ALLOB (allogeneic bone cell therapy) represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
The proceeds of the financing will contribute to continuing to advance the clinical development of Bone Therapeutics’ lead asset, its allogeneic bone cell therapy, ALLOB.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ABO Securities
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Agreement May 31, 2022
Details:
The proceeds of the financing will be used to advance the clinical development of Bone Therapeutics’ lead asset, the allogeneic bone cell therapy, ALLOB.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ABO Securities
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Financing April 12, 2022
Details:
Catalent has purchased the shares of SCTS and a purpose-built CGxP facility of approximately 41,000 square-foot. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product.
Lead Product(s): ALLOB
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 16, 2020
Details:
Agreements will streamline and economize the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus on the development of products from its differentiated MSC platform of cell and gene therapy.
Lead Product(s): ALLOB
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: $14.2 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 30, 2020
Details:
The 24 month follow-up data of this Phase IIa clinical trial have shown that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months.
Lead Product(s): ALLOB
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020